NeoGenomics (NEO) has returned to investor focus after recent trading swings, with the share price up around 20% over the past month but showing a decline over the past 3 months.

That recent rebound sits against a weaker backdrop, with a 90 day share price return of roughly a 31% decline and a 1 year total shareholder return of about a 14% decline, suggesting momentum is only just starting to recover.

If you are tracking shifts in market sentiment around healthcare and diagnostics, it can help to widen the lens and review other specialised medical testing names through 32 healthcare AI stocks

So with NeoGenomics sharing a long run of weak returns but recent double digit gains, and trading around a 35% discount to the average analyst price target, is this a reset entry point or is the market already reflecting its growth potential?

Most Popular Narrative: 39.3% Undervalued

At a last close of $8.61 versus a narrative fair value of $14.19, the prevailing view on NeoGenomics prices in a sizeable upside gap that hinges on specific product and reimbursement milestones playing out.

The commercial launch of PanTracer, a comprehensive liquid biopsy panel for therapy selection, is set to enhance NeoGenomics' competitiveness and capture greater share in the rapidly growing NGS and liquid biopsy segment, supporting revenue acceleration and higher average unit prices (AUP) through 2025 and beyond.

Curious what earnings power sits behind that fair value, and why it implies a rich future profit multiple for an unprofitable lab player today? The narrative leans on steady test volume expansion, firmer reimbursement, and a step change in margins to bridge today’s losses to tomorrow’s earnings engine.

Result: Fair Value of $14.19 (UNDERVALUED)

However, this hinges on pharma demand stabilising and new tests scaling smoothly, while competition and product or reimbursement setbacks could quickly undercut that upside story.

Another Angle: Multiples Send a Caution Flag

While the narrative fair value of $14.19 suggests upside, the current P/S of about 1.5x sits above both the US Healthcare average of 1.2x and peer average of 1x, as well as an estimated fair ratio of 1.2x. That premium points to less margin for error if growth or profitability slips.

For a closer look at how this pricing gap compares with peers and that fair ratio, check the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals across valuation and sentiment, this is a moment to move quickly and test the numbers yourself; start by weighing its 1 key reward and 1 important warning sign

Looking for more investment ideas?

If NeoGenomics has you thinking about portfolio upgrades, do not stop here. Broaden your watchlist with a few curated stock ideas built from clear, transparent data.

• Spot potential value candidates early by scanning 53 high quality undervalued stocks that combine quality fundamentals with prices that sit below their assessed worth.
• Prioritise resilience by reviewing 73 resilient stocks with low risk scores focused on companies with stronger risk profiles and steadier financial characteristics.
• Hunt for fresh names off the beaten path through the screener containing 25 high quality undiscovered gems that highlight lesser known businesses with solid underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.